Stockreport

NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer [Yahoo! Finance]

NovaBridge Biosciences - American Depositary Shares  (NBP) 
PDF NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response rate (ORR) as a primary endpoint for accelerated [Read more]